FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3198947401> ?p ?o ?g. }

• W3198947401 endingPage "e2123923" @default.
• W3198947401 startingPage "e2123923" @default.
• W3198947401 abstract "The most important surrogate for increased risk of adverse clinical outcomes among patients with nonalcoholic fatty liver disease (NAFLD) is the patient's stage of liver fibrosis. There is a significant barrier to risk-stratifying patients in clinical practice owing to the need for liver biopsy.To determine the performance of the enhanced liver fibrosis (ELF) test as a noninvasive test for assessment of liver fibrosis among patients with NAFLD.This retrospective cross-sectional study was conducted among patients recruited from a large, community-based hospital system's outpatient liver clinic from 2001 to 2020. Patients with NAFLD defined as steatosis greater than 5% without evidence of other liver disease or excessive alcohol use were included. Data were analyzed from August 2020 through February 2021.Enhanced liver fibrosis score was calculated.Advanced fibrosis was identified by liver biopsy or transient elastography.Among 829 patients with NAFLD, the mean (SD) age was 53.1 (14.0) years, there were 363 (43.8%) men, 294 patients (35.5%) had type 2 diabetes, and the mean (SD) fibrosis-4 (fib-4) score was 1.34 (0.97). There were 463 patients with liver biopsy, among whom 113 individuals (24.4%) had bridging fibrosis or cirrhosis; among 462 patients with transient elastography data, 79 individuals (17.1%) had liver stiffness results of 9.6 kPa or more (ie, advanced fibrosis). Patients with advanced fibrosis had statistically significantly increased mean (SD) ELF scores compared with patients without advanced fibrosis as determined by biopsy (10.1 [1.3] vs 8.6 [1.0]; P < .001) or transient elastography (10.0 [1.1] vs 9.0 [0.8]; P < .001). Among all patients with NAFLD, the area under the receiver operating characteristic curve (AUROC) for ELF in identifying patients with advanced fibrosis was 0.81 (95% CI, 0.77-0.85) for patients diagnosed by biopsy and 0.79 (95% CI, 0.75-0.82) for those diagnosed by transient elastography. Performance of the ELF score was similar among patients with NAFLD who were aged 65 years or older (AUROC, 0.74; 95% CI, 0.58-0.87) or had type 2 diabetes (AUROC, 0.78; 95% CI, 0.71-0.84). The combination of an ELF score of 7.2 or greater with a fib-4 score of 0.74 or greater was associated with a negative predictive value of 95.1% (95% CI, 91.8%-98.4%) and a sensitivity of 92.5% (95% CI, 87.4%-97.5%), which can reliably rule out advanced fibrosis. An ELF score of 9.8 or greater with a fib-4 score of 2.9 or greater was associated with a positive predictive value of 95.0% (95% CI, 85.5%-100%) and a specificity of 99.7% (95% CI, 99.1%-100%), which can be used to rule in advanced fibrosis.These findings suggest that the ELF test performs well in identifying patients with NAFLD who are at increased risk of advanced fibrosis and that this test combined with fib-4 score may be reliably used in clinical practice to assess the presence or absence of advanced fibrosis among patients with NAFLD." @default.
• W3198947401 created "2021-09-27" @default.
• W3198947401 creator A5002249547 @default.
• W3198947401 creator A5002917529 @default.
• W3198947401 creator A5003434284 @default.
• W3198947401 creator A5017966515 @default.
• W3198947401 creator A5019796339 @default.
• W3198947401 creator A5034894981 @default.
• W3198947401 creator A5037741510 @default.
• W3198947401 creator A5040042776 @default.
• W3198947401 creator A5065504305 @default.
• W3198947401 creator A5070138453 @default.
• W3198947401 creator A5071309777 @default.
• W3198947401 creator A5074202766 @default.
• W3198947401 creator A5080386622 @default.
• W3198947401 creator A5084895513 @default.
• W3198947401 date "2021-09-16" @default.
• W3198947401 modified "2023-10-12" @default.
• W3198947401 title "Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease" @default.
• W3198947401 cites W1574141134 @default.
• W3198947401 cites W2019093082 @default.
• W3198947401 cites W2067740038 @default.
• W3198947401 cites W2147372056 @default.
• W3198947401 cites W2156792510 @default.
• W3198947401 cites W216121951 @default.
• W3198947401 cites W2204688218 @default.
• W3198947401 cites W2580009538 @default.
• W3198947401 cites W2734724639 @default.
• W3198947401 cites W2759630103 @default.
• W3198947401 cites W2902751315 @default.
• W3198947401 cites W2912289473 @default.
• W3198947401 cites W2915339991 @default.
• W3198947401 cites W2954348899 @default.
• W3198947401 cites W2957317165 @default.
• W3198947401 cites W2957608484 @default.
• W3198947401 cites W2961805721 @default.
• W3198947401 cites W3015772154 @default.
• W3198947401 cites W3037759253 @default.
• W3198947401 cites W3112934795 @default.
• W3198947401 cites W3135385600 @default.
• W3198947401 cites W3158704946 @default.
• W3198947401 cites W3181177767 @default.
• W3198947401 cites W4211191129 @default.
• W3198947401 cites W4229826782 @default.
• W3198947401 cites W4237805430 @default.
• W3198947401 cites W4240656667 @default.
• W3198947401 cites W4241721607 @default.
• W3198947401 cites W4247038511 @default.
• W3198947401 cites W4247369539 @default.
• W3198947401 cites W4253826761 @default.
• W3198947401 doi "https://doi.org/10.1001/jamanetworkopen.2021.23923" @default.
• W3198947401 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8446814" @default.
• W3198947401 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34529067" @default.
• W3198947401 hasPublicationYear "2021" @default.
• W3198947401 type Work @default.
• W3198947401 sameAs 3198947401 @default.
• W3198947401 citedByCount "24" @default.
• W3198947401 countsByYear W31989474012022 @default.
• W3198947401 countsByYear W31989474012023 @default.
• W3198947401 crossrefType "journal-article" @default.
• W3198947401 hasAuthorship W3198947401A5002249547 @default.
• W3198947401 hasAuthorship W3198947401A5002917529 @default.
• W3198947401 hasAuthorship W3198947401A5003434284 @default.
• W3198947401 hasAuthorship W3198947401A5017966515 @default.
• W3198947401 hasAuthorship W3198947401A5019796339 @default.
• W3198947401 hasAuthorship W3198947401A5034894981 @default.
• W3198947401 hasAuthorship W3198947401A5037741510 @default.
• W3198947401 hasAuthorship W3198947401A5040042776 @default.
• W3198947401 hasAuthorship W3198947401A5065504305 @default.
• W3198947401 hasAuthorship W3198947401A5070138453 @default.
• W3198947401 hasAuthorship W3198947401A5071309777 @default.
• W3198947401 hasAuthorship W3198947401A5074202766 @default.
• W3198947401 hasAuthorship W3198947401A5080386622 @default.
• W3198947401 hasAuthorship W3198947401A5084895513 @default.
• W3198947401 hasBestOaLocation W31989474011 @default.
• W3198947401 hasConcept C126322002 @default.
• W3198947401 hasConcept C134018914 @default.
• W3198947401 hasConcept C2775934546 @default.
• W3198947401 hasConcept C2776175330 @default.
• W3198947401 hasConcept C2776954865 @default.
• W3198947401 hasConcept C2777075537 @default.
• W3198947401 hasConcept C2777214474 @default.
• W3198947401 hasConcept C2777766500 @default.
• W3198947401 hasConcept C2778772119 @default.
• W3198947401 hasConcept C2779102576 @default.
• W3198947401 hasConcept C2779134260 @default.
• W3198947401 hasConcept C2780559512 @default.
• W3198947401 hasConcept C2780826214 @default.
• W3198947401 hasConcept C555293320 @default.
• W3198947401 hasConcept C71924100 @default.
• W3198947401 hasConcept C90924648 @default.
• W3198947401 hasConceptScore W3198947401C126322002 @default.
• W3198947401 hasConceptScore W3198947401C134018914 @default.
• W3198947401 hasConceptScore W3198947401C2775934546 @default.
• W3198947401 hasConceptScore W3198947401C2776175330 @default.
• W3198947401 hasConceptScore W3198947401C2776954865 @default.
• W3198947401 hasConceptScore W3198947401C2777075537 @default.
• W3198947401 hasConceptScore W3198947401C2777214474 @default.

• next